Efficient Sleeping Beauty DNA transposition from DNA minicircles

Molecular Therapy Nucleic Acids

Volumn 2, Issue , 2013, Pages e74-

  Sharma, Nynne ^a   Cai, Yujia ^a   Bak, Rasmus O ^a   Jakobsen, Martin R ^a   Schrøder, Lisbeth Dahl ^a   Mikkelsen, Jacob Giehm ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Antibiotic resistance marker; DNA transposition; Minicircle; Plasmid backbone; Sleeping Beauty

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; MINICIRCLE DNA; TRANSPOSASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA TRANSPOSITION; DNA VECTOR; EXPRESSION VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SLEEPING BEAUTY DNA TRANSPOSON;

EID: 84878881733     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.1     Document Type: Article

References (50)

1. Izsvák, Z, Hackett, PB, Cooper, LJ and Ivics, Z (2010). Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. Bioessays 32: 756-767.
2. Aronovich, EL, McIvor, RS and Hackett, PB (2011). The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum Mol Genet 20(R1): R14-R20.
3. Ivics, Z, Hackett, PB, Plasterk, RH and Izsvák, Z (1997). Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 91: 501-510. (Pubitemid 27508239)
4. Cui, Z, Geurts, AM, Liu, G, Kaufman, CD and Hackett, PB (2002). Structure-function analysis of the inverted terminal repeats of the sleeping beauty transposon. J Mol Biol 318: 1221-1235. (Pubitemid 34753993)
5. Zayed, H, Izsvák, Z, Walisko, O and Ivics, Z (2004). Development of hyperactive sleeping beauty transposon vectors by mutational analysis. Mol Ther 9: 292-304. (Pubitemid 38256555)
6. Yant, SR, Park, J, Huang, Y, Mikkelsen, JG and Kay, MA (2004). Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells. Mol Cell Biol 24: 9239-9247. (Pubitemid 39313924)
7. Baus, J, Liu, L, Heggestad, AD, Sanz, S and Fletcher, BS (2005). Hyperactive transposase mutants of the Sleeping Beauty transposon. Mol Ther 12: 1148-1156. (Pubitemid 41723049)
8. Mátés, L, Chuah, MK, Belay, E, Jerchow, B, Manoj, N, Acosta-Sanchez, A et al. (2009). Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 41: 753-761.
9. Wilber, A, Frandsen, JL, Geurts, JL, Largaespada, DA, Hackett, PB and McIvor, RS (2006). RNA as a source of transposase for Sleeping Beauty-mediated gene insertion and expression in somatic cells and tissues. Mol Ther 13: 625-630. (Pubitemid 43257631)
10. Wilber, A, Wangensteen, KJ, Chen, Y, Zhuo, L, Frandsen, JL, Bell, JB et al. (2007). Messenger RNA as a source of transposase for sleeping beauty transposon-mediated correction of hereditary tyrosinemia type I. Mol Ther 15: 1280-1287. (Pubitemid 46965324)
11. Jin, Z, Maiti S, Huls, H, Singh, H, Olivares, S, Mátés, L et al. (2011). The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther 18: 849-56.
12. Wilber, A, Linehan, JL, Tian, X, Woll, PS, Morris, JK, Belur, LR et al. (2007). Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer. Stem Cells 25: 2919-2927. (Pubitemid 350127877)
13. Yant, SR, Huang, Y, Akache, B and Kay, MA (2007). Site-directed transposon integration in human cells. Nucleic Acids Res 35: e50.
14. Ivics, Z, Katzer, A, Stüwe, EE, Fiedler, D, Knespel, S and Izsvák, Z (2007). Targeted Sleeping Beauty transposition in human cells. Mol Ther 15: 1137-1144. (Pubitemid 46813616)
15. Hollis, RP, Nightingale, SJ, Wang, X, Pepper, KA, Yu, XJ, Barsky, L et al. (2006). Stable gene transfer to human CD34(+) hematopoietic cells using the Sleeping Beauty transposon. Exp Hematol 34: 1333-1343. (Pubitemid 44374844)
16. Sumiyoshi, T, Holt, NG, Hollis, RP, Ge, S, Cannon, PM, Crooks, GM et al. (2009). Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system. Hum Gene Ther 20: 1607-1626.
17. Xue, X, Huang, X, Nodland, SE, Mátés, L, Ma, L, Izsvák, Z et al. (2009). Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood 114: 1319-1330.
18. Singh, H, Manuri, PR, Olivares, S, Dara, N, Dawson, MJ, Huls, H et al. (2008). Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 68: 2961-2971. (Pubitemid 351556297)
19. Huang, X, Guo, H, Kang, J, Choi, S, Zhou, TC, Tammana, S et al. (2008). Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+lymphoid malignancies. Mol Ther 16: 580-589. (Pubitemid 351314999)
20. Huang, X, Wilber, A, McIvor, RS and Zhou, X (2009). DNA transposons for modification of human primary T lymphocytes. Methods Mol Biol 506: 115-126.
21. Orbán, TI, Apáti, A, Németh, A, Varga, N, Krizsik, V, Schamberger, A et al. (2009). Applying a "double-feature" promoter to identify cardiomyocytes differentiated from human embryonic stem cells following transposon-based gene delivery. Stem Cells 27: 1077-1087.
22. Ohlfest, JR, Frandsen, JL, Fritz, S, Lobitz, PD, Perkinson, SG, Clark, KJ et al. (2005). Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood 105: 2691-2698. (Pubitemid 40446258)
23. Liu, L, Mah, C and Fletcher, BS (2006). Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon. Mol Ther 13: 1006-1015.
24. Kren, BT, Unger, GM, Sjeklocha, L, Trossen, AA, Korman, V, Diethelm-Okita, BM et al. (2009). Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J Clin Invest 119: 2086-2099.
25. Belur, LR, Frandsen, JL, Dupuy, AJ, Ingbar, DH, Largaespada, DA, Hackett, PB et al. (2003). Gene insertion and long-term expression in lung mediated by the Sleeping Beauty transposon system. Mol Ther 8: 501-507. (Pubitemid 37161472)
26. Liu, L, Sanz, S, Heggestad, AD, Antharam, V, Notterpek, L and Fletcher, BS (2004). Endothelial targeting of the Sleeping Beauty transposon within lung. Mol Ther 10: 97-105. (Pubitemid 38885655)
27. Liu, H, Liu, L, Fletcher, BS and Visner, GA (2006). Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis. FASEB J 20: 2384-2386.
28. Belur, LR, Podetz-Pedersen, K, Frandsen, J and McIvor, RS (2007). Lung-directed gene therapy in mice using the nonviral Sleeping Beauty transposon system. Nat Protoc 2: 3146-3152.
29. Lin, EH, Keramidas, M, Rome, C, Chiu, WT, Wu, CW, Coll, JL et al. (2011). Lifelong reporter gene imaging in the lungs of mice following polyethyleneimine-mediated sleeping-beauty transposon delivery. Biomaterials 32: 1978-1985.
30. Wu, A, Oh, S, Ericson, K, Demorest, ZL, Vengco, I, Gharagozlou, S et al. (2007). Transposon-based interferon gamma gene transfer overcomes limitations of episomal plasmid for immunogene therapy of glioblastoma. Cancer Gene Ther 14: 550-560. (Pubitemid 46788330)
31. Ohlfest, JR, Lobitz, PD, Perkinson, SG and Largaespada, DA (2004). Integration and long-term expression in xenografted human glioblastoma cells using a plasmid-based transposon system. Mol Ther 10: 260-268. (Pubitemid 39117872)
32. Williams, DA (2008). Sleeping beauty vector system moves toward human trials in the United States. Mol Ther 16: 1515-1516.
33. Vandermeulen, G, Marie, C, Scherman, D and Préat, V (2011). New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials. Mol Ther 19: 1942-1949.
34. Tan, Y, Li, S, Pitt, BR and Huang, L (1999). The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum Gene Ther 10: 2153-2161. (Pubitemid 29416295)
35. Yew, NS and Cheng, SH (2004). Reducing the immunostimulatory activity of CpGcontaining plasmid DNA vectors for non-viral gene therapy. Expert Opin Drug Deliv 1: 115-125. (Pubitemid 40297960)
36. Darquet, AM, Rangara, R, Kreiss, P, Schwartz, B, Naimi, S, Delaère, P et al. (1999). Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer. Gene Ther 6: 209-218. (Pubitemid 29089919)
37. Chen, ZY, He, CY, Ehrhardt, A and Kay, MA (2003). Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 8: 495-500. (Pubitemid 37161471)
38. Chang, CW, Christensen, LV, Lee, M and Kim, SW (2008). Efficient expression of vascular endothelial growth factor using minicircle DNA for angiogenic gene therapy. J Control Release 125: 155-163. (Pubitemid 50008037)
39. Huang, M, Chen, Z, Hu, S, Jia, F, Li, Z, Hoyt, G et al. (2009). Novel minicircle vector for gene therapy in murine myocardial infarction. Circulation 120(11 Suppl): S230-S237.
40. Osborn, MJ, McElmurry, RT, Lees, CJ, DeFeo, AP, Chen, ZY, Kay, MA et al. (2011). Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of a-L-iduronidase in mice with mucopolysaccharidosis type I. Mol Ther 19: 450-460.
41. Wu, J, Xiao, X, Zhao, P, Xue, G, Zhu, Y, Zhu, X et al. (2006). Minicircle-IFNgamma induces antiproliferative and antitumoral effects in human nasopharyngeal carcinoma. Clin Cancer Res 12: 4702-4713. (Pubitemid 44297824)
42. Stenler, S, Andersson, A, Simonson, OE, Lundin, KE, Chen, ZY, Kay, MA et al. (2009). Gene transfer to mouse heart and skeletal muscles using a minicircle expressing human vascular endothelial growth factor. J Cardiovasc Pharmacol 53: 18-23.
43. Kay, MA, He, CY and Chen, ZY (2010). A robust system for production of minicircle DNA vectors. Nat Biotechnol 28: 1287-1289.
44. Yant, SR and Kay, MA (2003). Nonhomologous-end-joining factors regulate DNA repair fidelity during Sleeping Beauty element transposition in mammalian cells. Mol Cell Biol 23: 8505-8518. (Pubitemid 37433358)
45. Moldt, B, Miskey, C, Staunstrup, NH, Gogol-Döring, A, Bak, RO, Sharma, N et al. (2011). Comparative genomic integration profiling of Sleeping Beauty transposons mobilized with high efficacy from integrase-defective lentiviral vectors in primary human cells. Mol Ther 19: 1499-1510.
46. Mayrhofer, P, Schleef, M and Jechlinger, W (2009). Use of minicircle plasmids for gene therapy. Methods Mol Biol 542: 87-104.
47. Krieg, AM, Yi, AK, Matson, S, Waldschmidt, TJ, Bishop, GA, Teasdale, R et al. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549.
48. Dalsgaard, T, Moldt, B, Sharma, N, Wolf, G, Schmitz, A, Pedersen, FS et al. (2009). Shielding of sleeping beauty DNA transposon-delivered transgene cassettes by heterologous insulators in early embryonal cells. Mol Ther 17: 121-130.
49. Yant, SR, Meuse, L, Chiu, W, Ivics, Z, Izsvak, Z and Kay, MA (2000). Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 25: 35-41. (Pubitemid 30257033)
50. Sharma, N, Hollensen, AK, Bak, RO, Staunstrup, NH, Schrøder, LD and Mikkelsen, JG (2012). The impact of cHS4 insulators on DNA transposon vector mobilization and silencing in retinal pigment epithelium cells. PLoS ONE 7: e48421.